Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

WT1 Peptide Vaccine Is Able to Induce WT1-Specifc Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia

Hongtao Liu, MD PhD, Yuanyuan Zha, PhD, Gregory Malnassy, Noreen Fulton, Margaret Green, Jae-Hyun Park, PhD, Yusuke Nakamura, MD, Richard A. Larson, MD, Andres M Salazar, Olatoyosi Odenike, MD, Thomas Gajewski, MD PhD, Wendy Stock, MD

Blood (2016) 128 (22): 3984.

https://doi.org/10.1182/blood.V128.22.3984.3984

Published: 2016

Journal Articles

Combination of Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) Is Feasible and Tolerable

Amy Y Wang, MD, Howie Lawrence Weiner, Margaret Green, Richard A. Larson, MD, Olatoyosi Odenike, MD, Andrew Artz, MD, Lucy A Godley, MD, PhD, Michael J. Thirman, MD, Jane E Churpek, MD, Emily K. Curran, MD, Kristen Pettit, MD, Wendy Stock, MD, Hongtao Liu, MDPhD

Blood (2016) 128 (22): 212.

https://doi.org/10.1182/blood.V128.22.212.212

Published: 2016

Journal Articles

Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)

Yasmin H Karimi, MD, Nitin Jain, MD, Margaret Green, Lucy A Godley, MD, PhD, Howie Lawrence Weiner, Gregory Malnassy, Noreen Fulton, Andrew Artz, MD MS, Hongtao Liu, MDPhD, Michael J. Thirman, MD, Michael Daunov, Richard A. Larson, MD, Wendy Stock, MD, Olatoyosi Odenike, MD

Blood (2015) 126 (23): 3777.

https://doi.org/10.1182/blood.V126.23.3777.3777

Published: 2015

Journal Articles

Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).

Blood (2009) 114 (22): 2081.

https://doi.org/10.1182/blood.V114.22.2081.2081

Published: 2009

Journal Articles

High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).

Sarah Larson, MD, Nicholas Campbell, MD, Dezheng Huo, PhD, Andrew Artz, MD, MS, Yanming Zhang, Devika Gajria, Margaret Green, Gamar Rahimova, Howard Weiner, Monica Torres, Olatoyosi Odenike, MD, Lucy A Godley, MD, PhD, Elizabeth Shima Rich, MD, PhD, Michael Thirman, MD, Richard A. Larson, MD, Wendy Stock, MD

Blood (2009) 114 (22): 1048.

https://doi.org/10.1182/blood.V114.22.1048.1048

Published: 2009

Journal Articles

Treatment of Therapy-Related Myeloid Neoplasms with High-Dose Cytarabine/Mitoxantrone Followed by Hematopoietic Cell Transplantation (HCT).

Lucy A Godley, Uchenna O. Njiaju, Margaret Green, Howard Weiner, Shang Lin, PhD, Olatoyosi Odenike, MD, Elizabeth Shima Rich, MD, PhD, Andrew Artz, MD, MS, Koen van Besien, MD, Christopher Daugherty, MD, Yanming Zhang, Michelle M. Le Beau, PhD, Wendy Stock, MD, Richard A. Larson, MD

Blood (2009) 114 (22): 1030.

https://doi.org/10.1182/blood.V114.22.1030.1030

Published: 2009

Journal Articles

Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis

Olatoyosi M Odenike, John E. Godwin, Koen Van Besien, Dezheng Huo, Dorie Sher, Patrick Burke, Scott E. Smith, Margaret Green, Julia Melnick, James L Wade, Eric P. Lester, Rebecca B. Klisovic, Maria R. Baer, Richard A Larson, Wendy Stock

Blood (2008) 112 (11): 2809.

https://doi.org/10.1182/blood.V112.11.2809.2809

Published: 2008

Journal Articles

Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia.

Olatoyosi M. Odenike, John E. Godwin, Koen van Besien, Dezheng Huo, Patrick J. Stiff, Dorie Sher, Nicole Klekowski, Margaret Green, Richard A. Larson, Wendy Stock

Blood (2006) 108 (11): 4923.

https://doi.org/10.1182/blood.V108.11.4923.4923

Published: 2006

NARROW

WT1 Peptide Vaccine Is Able to Induce WT1-Specifc Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia

Combination of Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML) Is Feasible and Tolerable

Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)

Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).

High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).

Treatment of Therapy-Related Myeloid Neoplasms with High-Dose Cytarabine/Mitoxantrone Followed by Hematopoietic Cell Transplantation (HCT).

Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis

Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only